Ovarian cancer (relapsed) - trabectedin: final appraisal determination March 2011
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Trabectedin for the treatment of relapsed ovarian cancer and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 25th March 2011.
Ovarian cancer (relapsed) - trabectedin: final appraisal determination
Ovarian cancer (relapsed) - trabectedin: FAD - letter from the Department of Health
Ovarian cancer (relapsed) - trabectedin: FAD - manufacturer submission from PharmaMar
Ovarian cancer (relapsed) - trabectedin: FAD - evidence review group critique
Ovarian cancer (relapsed) - trabectedin: FAD - evidence review group critique - factual accuracies
Ovarian cancer (relapsed) - trabectedin: FAD - evidence review group - addendum to critique
Ovarian cancer (relapsed) - trabectedin: FAD -evidence review group - addendum to critique factual accuracies
This page was last updated: 11 March 2011

